切换至 "中华医学电子期刊资源库"
高级检索
中华普通外科学文献(电子版)

中华普通外科学文献(电子版) ›› 2013, Vol. 07 ›› Issue (04) : 260 -264. doi: 10.3877/cma.j.issn.1674-0793.2013.04.005

所属专题： 文献；

论著

孕激素受体a、b在乳腺浸润性导管癌中的表达及意义
黄泽楠1, 冯智英2, 刘宇1, 陈健宁2, 胡攀1, 潘宇航2, 刘仁斌1,†()   
  1. 1. 510630　广州，中山大学附属第三医院乳腺外科
    2. 510630　广州，中山大学附属第三医院病理科
  • 收稿日期:2012-09-01 出版日期:2013-08-01
  • 通信作者: 刘仁斌

Expressions of progesterone receptor a and b in breast invasive ductal carcinoma and their clinical significance

Ze-nan HUANG1, Zhi-ying FENG2, Yu LIU1, Jian-ning CHEN2, Pan HU1, Yu-hang PAN2, Ren-bin LIU1,†()   

  1. 1. Department of Breast Surgery, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China
  • Received:2012-09-01 Published:2013-08-01
  • Corresponding author: Ren-bin LIU
  • About author:
    Corresponding author: LIU Ren-bin, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

黄泽楠, 冯智英, 刘宇, 陈健宁, 胡攀, 潘宇航, 刘仁斌. 孕激素受体a、b在乳腺浸润性导管癌中的表达及意义[J]. 中华普通外科学文献(电子版), 2013, 07(04): 260-264.

Ze-nan HUANG, Zhi-ying FENG, Yu LIU, Jian-ning CHEN, Pan HU, Yu-hang PAN, Ren-bin LIU. Expressions of progesterone receptor a and b in breast invasive ductal carcinoma and their clinical significance[J]. Chinese Archives of General Surgery(Electronic Edition), 2013, 07(04): 260-264.

目的

探讨孕激素受体a（PR-a）、孕激素受体b（PR-b）在乳腺浸润性导管癌（IDC）中的表达及其与各临床病理指标的相关性，探讨PR亚型与预后的关系。

方法

采用免疫组化法检测100例IDC组织中PR-a、PR-b的表达，分析其与雌激素受体α（ER-α）、雌激素受体β（ER-β）、人类表皮生长因子受体2（HER-2）、核增殖抗原Ki-67、淋巴结转移、细胞学分级、TNM分期及脉管癌栓的相关性，研究PR-a/PR-b比值与各指标的关系。

结果

PR-a阳性55例（55%），PR-b阳性58例（58%）。PR-a与HER-2、Ki-67的表达呈正相关（P < 0.05），与淋巴结转移负相关（P < 0.05），与ER-β及脉管癌栓负相关（P < 0.01），与ER-α、细胞学分级、TNM分期无相关；PR-b与淋巴结转移、细胞学分级、TNM分期负相关（P < 0.05），与HER-2、Ki-67及脉管癌栓亦呈负相关（P < 0.01），与ER-α、ER-β无相关。PR-a/PR-b>1者32例（48.5%），=1者18例（27.3%），< 1者16例（24.2%）。PR-a/PR-b > 1组的HER-2、Ki-67、高细胞学分级、高TNM分期、淋巴结阳性率高于PR-a/PR-b≤1组（P < 0.05）。

结论

PR-b的表达与HER-2、Ki-67、淋巴结转移、细胞学分级、TNM分期及脉管癌栓均呈负相关，而PR-a与各指标的相关性各不相同，PR-b阳性及PR-a/PR-b≤1可作为IDC预后良好的指标。

关键词: 浸润性导管癌, 孕激素受体a, 孕激素受体b, 预后
Objective

To investigate the expressions of progesterone receptor a and b in breast invasive ductal carcinoma(IDC) and their associations with clinical and pathological factors and prognosis.

Methods

The expressions of PR-a and PR-b in 100 specimens of IDC were detected by immunohistochemistry. The correlations between PR-a, PR-b and characteristics such as ER-α, ER-β, HER-2, Ki-67, axillary lymph node(ALN)metastases, cytological classification, TNM staging and lymphovascular invasion were analyzed, the relationships between PR-a/PR-b ratio and these factors were investigated.

Results

The expression rates of PR-a and PR-b were 55% and 58% respectively. The results showed positive correlation between PR-a and HER-2, Ki-67(P < 0.05), and negative correlation between PR-a and ALN metastases(P < 0.05), ER-β, lymphovascular invasion(P < 0.01), but irrelevant with ER-α, cytological classification, TNM staging. The results also showed that PR-b was negatively correlated with ALN metastases, cytological classification, TNM staging(P < 0.05), lymphovascular invasion, HER-2 and Ki-67(P < 0.01), although irrelevant with neither ER-α nor ER-β. The number of PR-a/PR-b > 1, =1 and <1 was 32(48.5%), 18(27.3%) and 16(24.2%) respectively. In PR-a/PR-b > 1 group, the positive rates of HER-2, Ki-67, high cytological classification, high TNM staging and ALN metastases were higher than PR-a/PR-b≤1 group(P < 0.05).

Conclusions

The expression of PR-b is negatively correlated with HER-2, Ki-67, ALN metastases, cytological classification, TNM staging and lymphovascular invasion. PR-b positive and PR-a/PR-b≤1 can be good indicators of prognosis for IDC.

Key words: Invasive ductal carcinoma(IDC), Progesterone receptor a(PR-a), Progesterone receptor b(PR-b), Prognosis
图1 乳腺浸润性导管癌PR-a、PR-b的表达（NovoLink Polymer检测法，400倍）
图2 PR-a与PR-b的差异性表达
表1 PR-a、PR-b与各指标的相关性[n/n(%)]（Spearman相关性分析）
? ER-α阳性 ER-β阳性 HER-2阳性 Ki-67阳性 淋巴结转移 细胞学分级Ⅲ级 TNM Ⅲ、Ⅳ期 脉管癌栓阳性
PR-a阳性 28/55(50.9) 19/55(34.5) 23/55(41.8) 35/55(63.6) 24/55(43.6) 21/55(38.2) 15/55(27.3) 5/55(9.1)
PR-a阴性 26/45(57.8) 28/45(62.2) 8/45(17.8) 19/45(42.2) 31/45(68.9) 26/45(57.8) 13/45(28.9) 14/45(31.1)
r值 -0.069 -0.276 0.259 0.214 -0.253 -0.195 -0.018 -0.279
P值 0.548 0.009 0.016 0.044 0.015 0.070 1.000 0.009
PR-b阳性 30/58(51.7) 28/58(48.3) 11/58(18.9) 21/58(34.5) 26/58(44.8) 22/58(37.9) 11/58(18.9) 5/58(8.6)
PR-b阴性 24/42(57.1) 19/42(45.2) 20/42(47.6) 33/42(78.6) 29/42(69.1) 25/42(59.5) 17/42(40.5) 14/42(33.3)
r值 -0.054 -0.03 -0.306 -0.42 -0.24 -0.214 -0.23 -0.311
P值 0.685 0.840 0.004 0.000 0.025 0.043 0.024 0.004
表2 PR-a/PR-b>1组与≤1组各指标阳性率的比较(χ2检验) [（%，n/n）]
PR-a/PR-b ER-α阳性 ER-β阳性 Ki-67阳性 HER-2阳性 脉管癌栓阳性 淋巴结转移 高细胞学分级(Ⅲ级) 高TNM分期(Ⅲ、Ⅳ期)
>1组 68.8(22/32) 50.0(16/32) 71.9(23/32) 46.9(15/32) 18.7(6/32) 65.6(21/32) 62.5(20/32) 46.9(15/32)
≤1组 35.3(12/34) 47.1 (16/34) 44.1(15/34) 20.6(7/34) 17.6(6/34) 35.3(12/34) 32.4(11/34) 14.7 (5/34)
χ2值 7.387 - 5.2 5.126 - 6.066 6.015 8.077
P值 0.008 1 0.027 0.036 1 0.026 0.026 0.007
1
Tirona MT, Sehgal R, Ballester O. Prevention of breast cancer (part I):epidemiology, risk factors, and risk assessment tools. Cancer Invest, 2010, 28(7): 743-750.
2
Delozier T. Hormonal treatment in breast cancer. J Gynecol Obstet Biol Reprod (Paris), 2010, 39(8 Suppl): F71-78.
3
Mc Cormack O, Harrison M, Kerin MJ, et al. Role of the progesterone receptor (PR) and the PR isoforms in breast cancer. Crit Rev Oncog,2007 ,13(4): 283-301.
4
Tong LC, Nelson N, Tsourigiannis J, et al. The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast cancer: a prospective study. Am J Surg Pathol, 2011, 35(4): 545-552.
5
Leong AS, Zhuang Z. The changing role of pathology in breast cancer diagnosis and treatment. Pathobiology, 2011, 78(2): 99-114.
6
陈光，范志民. 甲状腺、乳腺外科发展现状与展望[J/CD]. 中华普通外科学文献:电子版, 2010, 4(6): 515-517.
7
Elledge RM, Green S, Pugh R, et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer, 2000, 89(2): 111-117.
8
Sartorius CA, Melville MY, Hovland AR, et al. A third transactivation function (AF3) of human progesterone receptors located in the unique N-terminal segment of the B-isoform. Mol Endocrinol, 1994, 8(10): 1347-1360.
9
Horwitz KB, Alexander PS. In situ photolinked nuclear progesterone receptors of human breast cancer cells: subunit molecular weights after transformation and translocation. Endocrinology, 1983, 113(6): 2195-2201.
10
Wei LL, Gonzalez-Aller C, Wood WM, et al. 5'-Heterogeneity in human progesterone receptor transcripts predicts a new amino-terminal truncated "C"-receptor and unique A-receptor messages. Mol Endocrinol, 1990, 4(12): 1833-1840.
11
Flototto T, Niederacher D, Hohmann D, et al. Molecular mechanism of estrogen receptor(ER) alpha-specific, estradiol-dependent expression of the progesterone receptor(PR) B-isoform. J Steroid Biochem Mol Biol, 2004, 88(2): 131-142.
12
Lange CA, Sartorius CA, Abdel-Hafiz H, et al. Progesterone receptor action: translating studies in breast cancer models to clinical insights. Adv Exp Med Biol, 2008, 630: 94-111.
13
侯景辉，曾敬，吴慧瑜, 等. 表皮生长因子受体2和雌激素受体及孕激素受体在乳腺癌中的表达及相关性分析[J/CD]. 中华临床医师杂志:电子版, 2010, 4(6): 739-743.
14
Hopp TA, Weiss HL, Hilsenbeck SG, et al. Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res, 2004, 10(8): 2751-2760.
15
Hirche C, Mohr Z, Kneif S, et al. The role of nodal staging in breast cancer. Past, present and future. Minerva Chir, 2010, 65(5): 537-546.
16
Kim HJ, Cui X, Hilsenbeck SG, et al. Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer. Clin Cancer Res, 2006, 12(3 Pt 2): 1013s-1018s.
[1] 衣晓丽, 胡沙沙, 张彦. HER-2低表达对乳腺癌新辅助治疗疗效及预后的影响[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 340-346.
[2] 施杰, 李云涛, 高海燕. 腋窝淋巴结阳性Luminal A型乳腺癌患者新辅助与辅助化疗的预后及影响因素分析[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 353-361.
[3] 谭巧, 苏小涵, 侯令密, 黎君彦, 邓世山. 乳腺髓样癌的诊治进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 366-368.
[4] 李越洲, 张孔玺, 李小红, 商中华. 基于生物信息学分析胃癌中PUM的预后意义[J]. 中华普通外科学文献(电子版), 2023, 17(06): 426-432.
[5] 张俊, 罗再, 段茗玉, 裘正军, 黄陈. 胃癌预后预测模型的研究进展[J]. 中华普通外科学文献(电子版), 2023, 17(06): 456-461.
[6] 杨倩, 李翠芳, 张婉秋. 原发性肝癌自发性破裂出血急诊TACE术后的近远期预后及影响因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 33-36.
[7] 栗艳松, 冯会敏, 刘明超, 刘泽鹏, 姜秋霞. STIP1在三阴性乳腺癌组织中的表达及临床意义研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 52-56.
[8] 马伟强, 马斌林, 吴中语, 张莹. microRNA在三阴性乳腺癌进展中发挥的作用[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 111-114.
[9] 姜明, 罗锐, 龙成超. 闭孔疝的诊断与治疗：10年73例患者诊疗经验总结[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(06): 706-710.
[10] 潘冰, 吕少诚, 赵昕, 李立新, 郎韧, 贺强. 淋巴结清扫数目对远端胆管癌胰十二指肠切除手术疗效的影响[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 608-612.
[11] 张其坤, 商福超, 李琪, 栗光明, 王孟龙. 联合脾切除对肝癌合并门静脉高压症患者根治性切除术后的生存获益分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 613-618.
[12] 卢艳军, 马健, 白鹏宇, 郭凌宏, 刘海义, 江波, 白文启, 张毅勋. 纳米碳在腹腔镜直肠癌根治术中253组淋巴结清扫的临床效果[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 473-477.
[13] 李永胜, 孙家和, 郭书伟, 卢义康, 刘洪洲. 高龄结直肠癌患者根治术后短期并发症及其影响因素[J]. 中华临床医师杂志(电子版), 2023, 17(9): 962-967.
[14] 王军, 刘鲲鹏, 姚兰, 张华, 魏越, 索利斌, 陈骏, 苗成利, 罗成华. 腹膜后肿瘤切除术中大量输血患者的麻醉管理特点与分析[J]. 中华临床医师杂志(电子版), 2023, 17(08): 844-849.
[15] 索利斌, 刘鲲鹏, 姚兰, 张华, 魏越, 王军, 陈骏, 苗成利, 罗成华. 原发性腹膜后副神经节瘤切除术麻醉管理的特点和分析[J]. 中华临床医师杂志(电子版), 2023, 17(07): 771-776.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号